Research Study Comparing a New Medicine Fast-acting Insulin Aspart to Another Already Available Medicine NovoRapid/NovoLog in People With Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1264 participants.
Also called NCT03268005
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,264 participants
- Sponsor
- Registry
-
NCT03268005 -
2016-000878-38
-
- Other papers using this trial's data
- A Randomized Trial Evaluating the Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec With or Without Metformin, in Adults With Type 2 Diabetes (ONSET 9)
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Bulgaria, Canada, Croatia, Czechia, Germany, Greece, Italy, Poland, Puerto Rico, Romania, Russia, Serbia, Slovakia, South Korea, Spain, Ukraine
- Registry status
- Completed
Technical summary
Registry record NCT03268005. Randomized; quadruple masking; primary purpose treatment. Start 2017-09-19 (actual); primary completion 2019-01-07 (actual). Results posted on 2020-03-12.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Research Study Comparing a New Medicine "Fast-acting Insulin Aspart" to Another Already Available Medicine "NovoRapid"/"NovoLog" in People With Type 2 Diabetes
- Acronym
- onset 9
- Condition
- Diabetes
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Faster-acting insulin aspart
- Intervention (Drug)
- Insulin aspart
- Intervention (Drug)
- Insulin degludec
- Intervention (Drug)
- Metformin
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct03268005- Content hash
151a0b04e1994f263d3604e06b9670c117cb40034bd64d72b62500c341a7cd93